Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $23.34 USD
Change Today +0.21 / 0.91%
Volume 904.8K
HALO On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Kurt A. Gustafson

Former Chief Financial Officer, Principal Accounting Officer and Vice President, Halozyme Therapeutics, Inc.
AgeTotal Calculated CompensationThis person is connected to 18 board members in 2 different organizations across 4 different industries.

See Board Relationships
47$1,269,319
As of Fiscal Year 2013

Background*

Mr. Kurt A. Gustafson has been the Chief Financial Officer, Principal Accounting Officer and Executive Vice President of Spectrum Pharmaceuticals, Inc. since June 3, 2013. Mr. Gustafson served as the Chief Financial Officer of Halozyme Therapeutics, Inc. from May 15, 2009 to May 23, 2013 and also served as its Principal Accounting Officer and Vice President until May 23, 2013. He served as Vice President of Finance of Halozyme Therapeutics, Inc. since April 2009 and ...

Read Full Background

Corporate Headquarters*

11388 Sorrento Valley Road
San Diego, California 92121

United States

Phone: 858-794-8889
Fax: 858-704-8311

Board Members Memberships*

Director
2014-Present
Director, Chairman of Audit Committee and Member of Compensation Committee

Education*

BA
North Park University
MBA
University of California-Los Angeles

Other Affiliations*

Annual Compensation*

Salary$450,000
Bonus$225,000
Total Annual Compensation$675,000

Stock Options*

Restricted Stock Awards$180,750
All Other Compensation$104,119
Exercisable Options118,748
Unexercisable Options306,252
Total Number of Options425,000

Total Compensation*

Total Annual Cash Compensation$779,119
Total Short Term Compensation$675,000
Other Long Term Compensation$284,869
Total Calculated Compensation$1,269,319
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HALO:US $23.34 USD +0.21

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Ron Squarer BSc (Biochemistry), MBAChief Executive Officer and Director
Array BioPharma Inc.
$548.8K
James A. Bianco M.D.Principal Founder, Chief Executive Officer, President, Executive Director, Member of Scientific Advisory Board and Member of Executive Committee
CTI BioPharma Corp.
$1.3M
Raul R. Rodriguez Chief Executive Officer, President, Director and Member of Finance Committee
Rigel Pharmaceuticals, Inc.
$551.7K
Mark R. Baker J.D.Chief Executive Officer, Director and Member of Science & Strategy Committee
Progenics Pharmaceuticals, Inc.
$555.7K
Andrew Philip Witty Chief Executive Officer, Director, Member of Corporate Administration & Transactions Committee and Member of Finance Committee
GlaxoSmithKline S.A.E
--
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HALOZYME THERAPEUTICS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.